Tirzepatide Before and After: What Clinical Trials Show

What the Clinical Trials Actually Show

In SURMOUNT-1, adults without diabetes assigned to 15 mg tirzepatide lost an average of 20.9% of body weight at 72 weeks, compared with 3.1% in the placebo group.¹ Participants also received lifestyle intervention. These study results support FDA-approved Zepbound; they are not results established for Trimi's compounded tirzepatide.

The trial average describes a study group at a specific dose and time point. It does not promise that an individual will lose that amount, or establish a monthly weight-loss target.

The First Month: What Actually Happens

For reference, the FDA-approved Zepbound label starts at 2.5 mg once weekly for four weeks.³ Your licensed provider determines your prescription and dosing plan. Compounded tirzepatide is not FDA-approved; do not start or change a dose based on this article.

Topics to discuss during early follow-up:

• Tolerability: Tell your provider about side effects and whether you can eat and drink adequately.
• Response: Review your weight trend without treating one weigh-in as a promised milestone.
• Instructions: Confirm the prescribed dose and ask your provider or pharmacist about anything unclear.

Months 2-3: Reassessing Dose and Tolerability

The Zepbound label moves to 5 mg weekly after four weeks. Later increases are in 2.5 mg steps after at least four weeks at the current dose, up to 15 mg weekly.³ Changes require your provider's assessment.

A calendar alone does not decide the next dose. Report side effects before increasing treatment, and follow the instructions for your own prescription rather than another person's schedule.

Months 4-6: Reviewing the Maintenance Plan

Zepbound's labeled weight-management maintenance doses are 5 mg, 10 mg or 15 mg weekly.³ A provider selects treatment based on response and tolerability. Being several months into care does not mean everyone should reach the same dose.

Questions for your maintenance review:

• Is the current plan helping with the goals you discussed?
• Are any side effects affecting daily life or nutrition?
• Have your medical history or other medications changed?
• Does the plan need adjustment based on your provider's assessment?

Months 7-12 and Beyond: Longer-Term Decisions

Longer-term care includes deciding whether to continue, adjust or stop treatment. SURMOUNT-4 found weight regain after participants switched from study tirzepatide to placebo, despite continued lifestyle intervention.² These findings do not establish outcomes for compounded preparations.

Discuss the following with your provider:

• Whether any monitoring is appropriate for your medical history.
• The benefits and risks of continuing treatment.
• Any changes to the goals of care.
• A plan for follow-up if treatment changes or stops.

Why Results Vary (And That's Normal)

A trial average does not describe every participant. Your provider considers your individual circumstances when reviewing treatment, including:

Monitoring Beyond the Scale

Discuss health and daily functioning alongside weight. Examples of topics for review include:

• Blood sugar monitoring when clinically indicated.
• Blood pressure and any prescribed monitoring.
• Sleep symptoms and existing sleep-apnea treatment.
• Mobility and comfort with everyday activity.
• Eating patterns and any concerns about food intake.
• Your experience of treatment and quality of life.

A Provider-Guided Review Timeline

Use follow-up visits to assess the plan, rather than treating a month on the calendar as a weight-loss promise:

• Month 1: Clarify prescription instructions and report early symptoms.
• Months 2-3: Review response before any provider-directed dose change.
• Months 4-6: Reassess ongoing benefits, risks and nutrition.
• Months 7-12: Discuss longer-term treatment goals.
• Beyond 1 year: Continue follow-up according to your provider's plan.

Supporting Your Treatment Plan

Nutrition and physical activity were part of the clinical trial programs.^1,2 Ask your provider what is appropriate for your health and circumstances:

• Nutrition: Discuss protein intake and other nutritional needs with your provider.
• Activity: Discuss a suitable exercise plan, including strength training if appropriate.
• Hydration: Ask for guidance if symptoms interfere with drinking enough fluid.
• Sleep: Raise sleep concerns during follow-up.
• Wellbeing: Tell your provider about concerns affecting your care.
• Prescription instructions: Follow your own dosing schedule and ask about missed doses.

Interpreting Tirzepatide Results

Research informs a discussion about treatment. It does not supply a personal before-and-after forecast. Results vary, and evidence from trials supporting FDA-approved Zepbound must not be presented as outcomes established for Trimi's compounded preparations.

Your licensed provider determines eligibility, treatment selection and dose after reviewing your medical assessment.